Sichuan Kelun Pharmaceutical Co., Ltd.

002422

CNE100000PW7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
33.67 ^CNY	-0.12%		-2.94%	+15.90%

25/04	Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	CI
25/04	Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Sichuan Kelun Pharmaceutical Co., Ltd. Announces Cash Dividend on Share A for 2022, Payable on May 15, 2023

May 10, 2023 at 01:12 am IST

Sichuan Kelun Pharmaceutical Co., Ltd. announced Cash dividend/10 shares (tax included): CNY 6.16000000 on share A for 2022. Record date: 12 May 2023, Ex-date: 15 May 2023 and Payment date: 15 May 2023.

Latest news about Sichuan Kelun Pharmaceutical Co., Ltd.

Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	25/04	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	10/04	CI
US FDA to Accelerate Review of Kelun Pharma Unit's Lung Cancer Drug	12/03	MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%	23/01	MT
Kelun Pharmaceutical's Olaparib Tablets Get Nod from Chinese Drug Regulator	22/01	MT
Kelun Pharma Gets Registration Approval in China for Immune Thrombocytopenia Drug	17/01	MT
Kelun Pharma Sees Up to 50% Jump in 2023 Profit	16/01	MT
Kelun Pharma's Unit Gets US FDA's Orphan Drug Designation to A400	28/11	MT
Kelun Pharmaceutical's Unit Gains Registration Certificate for Ceftazidime Avibactam Sodium/Sodium Chloride Injection	01/11	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Kelun Pharma Ends Cancer Drug Contract, Revises Partnership With Merck	24/23/24	MT
Global markets live: Foxconn, Roche, Eli Lilly, Chevron, Apple...	23/23/23
The good, the bad and the ugly	23/23/23
Merck discontinues some cancer drug development with China's Sichuan Kelun	23/23/23	RE
Kelun Pharma Unit Obtains Registration Approval in China for Bacterial Infection Drug	18/23/18	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Sichuan Kelun Pharma to Start License Application Process For New Cancer Drug	15/23/15	MT
Kelun Pharma's Unit Gets Gadobutrol injection Certified	13/23/13	MT
Kelun Pharma Expects Up to 66% Jump in H1 Profit	05/23/05	MT
China's Sichuan Kelun-Biotech opens books for $208 million Hong Kong IPO - term sheet	28/23/28	RE
Kelun Pharma Registers GERD Drug in China	27/23/27	MT
Kelun Pharma Gets Nod for Nutritional Supplement	13/23/13	MT
Kelun Pharmaceutical Unit Kelun Biotech Begins Pre-Marketing Activities for Hong Kong IPO	06/23/06	MT
Sichuan Kelun Pharmaceutical Co., Ltd. Announces Cash Dividend on Share A for 2022, Payable on May 15, 2023	10/23/10	CI

Chart Sichuan Kelun Pharmaceutical Co., Ltd.

Duration

Period

Chart Sichuan Kelun Pharmaceutical Co., Ltd.

More charts

Company Profile

Sichuan Kelun Pharmaceutical Co., Ltd. specializes in developing, manufacturing and marketing pharmaceuticals. Net sales break down by activity as follows: - manufacturing and sale of pharmaceutical products (98%). Net sales break down by family of products between injectable drugs (56.9%) and other (43.1%; tablets, capsules, granules, etc.); - other (2%). China accounts for 94.6% of net sales.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sichuan Kelun Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

33.67 CNY

Average target price

42.04 CNY

Spread / Average Target

+24.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SICHUAN KELUN PHARMACEUTICAL CO., LTD.	+15.90%	741.7Cr
ELI LILLY AND COMPANY	+32.09%	69TCr
NOVO NORDISK A/S	+29.39%	58TCr
JOHNSON & JOHNSON	-1.34%	37TCr
MERCK & CO., INC.	+20.34%	33TCr
ABBVIE INC.	+7.39%	29TCr
ASTRAZENECA PLC	+14.25%	24TCr
ROCHE HOLDING AG	-3.03%	21TCr
NOVARTIS AG	+10.02%	21TCr
AMGEN INC.	+8.49%	17TCr

Other Pharmaceuticals